{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T05:48:06Z","timestamp":1792648086908,"version":"4.5.0"},"reference-count":179,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006595","name":"Unitatea Executiva pentru Finantarea Invatamantului Superior, a Cercetarii, Dezvoltarii si Inovarii","doi-asserted-by":"publisher","award":["PN-III-P4-ID-PCE-2020-2027 \/ PCE 153\/2021"],"award-info":[{"award-number":["PN-III-P4-ID-PCE-2020-2027 \/ PCE 153\/2021"]}],"id":[{"id":"10.13039\/501100006595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Immune checkpoint inhibitors, namely anti-CTLA-4, anti-PD-1 and anti-PD-L1 monoclonal antibodies, have emerged in the last decade as a novel form of cancer treatment, promoting increased survival in patients. As they tamper with the immune response in order to destroy malignant cells, a new type of adverse reactions has emerged, known as immune-related adverse events (irAEs), which frequently target the endocrine system, especially the thyroid and hypophysis. Thyroid irAEs include hyperthyroidism, thyrotoxicosis, hypothyroidism and a possibly life-threatening condition known as the \u201cthyroid storm\u201d. Early prediction of occurrence and detection of the thyroid irAEs should be a priority for the clinician, in order to avoid critical situations. Moreover, they are recently considered both a prognostic marker and a means of overseeing treatment response, since they indicate an efficient activation of the immune system. Therefore, a multidisciplinary approach including both oncologists and endocrinologists is recommended when immune checkpoint inhibitors are used in the clinic.<\/jats:p>","DOI":"10.3389\/fendo.2022.1010279","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:36:51Z","timestamp":1663634211000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":57,"title":["Thyroid-related adverse events induced by immune checkpoint inhibitors"],"prefix":"10.3389","volume":"13","author":[{"given":"Alexandra","family":"Chera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea Lucia","family":"Stancu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Octavian","family":"Bucur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.649863","article-title":"Immune checkpoint inhibitors-related thyroid dysfunction: Epidemiology, clinical presentation, possible pathogenesis, and management","volume":"12","author":"Zhan","year":"2021","journal-title":"Front Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2020.11.117","article-title":"Imaging spectrum of adverse events of immune checkpoint inhibitors","volume":"76","author":"Shroff","year":"2021","journal-title":"Clin Radiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B4","unstructured":"FDA Approves yervoy for late-stage melanoma2011"},{"key":"B5","doi-asserted-by":"publisher","first-page":"5277","DOI":"10.3390\/cancers13215277","article-title":"The continuum of thyroid disorders related to immune checkpoint inhibitors: Still many pending queries","volume":"13","author":"Deligiorgi","year":"2021","journal-title":"Cancers"},{"key":"B6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0921","article-title":"Immunotherapy-mediated thyroid dysfunction: Genetic risk and impact on outcomes with PD-1 blockade in non\u2013small cell lung cancer","volume":"27","author":"Luo","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S261433","article-title":"Thyroid dysfunctions due to immune checkpoint inhibitors: A review","volume":"13","author":"Sabbagh","year":"2020","journal-title":"Int J Gen Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-018-9463-2","article-title":"Thyroid disorders induced by checkpoint inhibitors","volume":"19","author":"Ferrari","year":"2018","journal-title":"Rev Endocrine Metab Disord"},{"key":"B10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2018","journal-title":"Endocrine Rev"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.3390\/ijms20102560","article-title":"Autoimmune endocrine dysfunctions associated with cancer immunotherapies","volume":"20","author":"Ferrari","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","first-page":"100011","DOI":"10.1016\/j.esmoop.2020.100011","article-title":"How we treat endocrine complications of immune checkpoint inhibitors","volume":"6","author":"Paschou","year":"2021","journal-title":"ESMO Open"},{"key":"B13","doi-asserted-by":"publisher","first-page":"101370","DOI":"10.1016\/j.beem.2019.101370","article-title":"New insight in endocrine-related adverse events associated to immune checkpoint blockade","volume":"34","author":"Elia","year":"2020","journal-title":"Best Pract Research: Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.894015","article-title":"Insights into the host contribution of endocrine associated immune-related adverse events to immune checkpoint inhibition therapy","volume":"12","author":"Chye","year":"2022","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-019-9579-2","article-title":"Pembrolizumab-induced thyroiditis","volume":"30","author":"Imblum","year":"2019","journal-title":"Endocrine Pathol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8698","article-title":"Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants","volume":"7","author":"Chowdhury","year":"2016","journal-title":"Oncotarget"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3934","DOI":"10.3390\/ijms20163934","article-title":"The immune landscape of thyroid cancer in the context of immune checkpoint inhibition","volume":"20","author":"Varricchi","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-017-0772-1","article-title":"Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution","volume":"41","author":"Guaraldi","year":"2018","journal-title":"J Endocrinological Invest"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40123-020-00317-y","article-title":"Considerations for use of immune checkpoint inhibitors in cancer therapy for patients with Co-existing thyroid eye disease","volume":"10","author":"Chau","year":"2021","journal-title":"Ophthalmol Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1205943","article-title":"Tumor immunotherapy directed at PD-1","volume":"366","author":"Ribas","year":"2012","journal-title":"New Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxm057","article-title":"PD-1 and PD-1 ligands: From discovery to clinical application","volume":"19","author":"Okazaki","year":"2007","journal-title":"Int Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0375","article-title":"Incidence of thyroid function test abnormalities in patients receiving immune-checkpoint inhibitors for cancer treatment","volume":"23","author":"Patel","year":"2018","journal-title":"Oncologist."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3746","article-title":"Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations","volume":"20","author":"Schubert","year":"2014","journal-title":"Nat Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-018-9540-9","article-title":"Papillary thyroid carcinoma emerging from hashimoto thyroiditis demonstrates increased PD-L1 expression, which persists with metastasis","volume":"29","author":"Lubin","year":"2018","journal-title":"Endocrine Pathol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1210\/js.2017-00432","article-title":"Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: A prospective study","volume":"2","author":"Kobayashi","year":"2018","journal-title":"J Endocrine Soc"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13800","article-title":"Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab","volume":"109","author":"Kimbara","year":"2018","journal-title":"Cancer Sci"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e114","DOI":"10.15190\/d.2020.11","article-title":"Importance of routine laboratory investigations before elective surgery","volume":"8","author":"Kannaujia","year":"2020","journal-title":"Discoveries"},{"key":"B30","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41587-021-01070-8","article-title":"Improved prediction of immune checkpoint blockade efficacy across multiple cancer types","volume":"40","author":"Chowell","year":"2022","journal-title":"Nat Biotechnol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: Utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/CJI.0000000000000392","article-title":"The prognostic significance of baseline neutrophil-to-Lymphocyte ratio in melanoma patients receiving immunotherapy","volume":"45","author":"Li","year":"2021","journal-title":"J Immunotherapy"},{"key":"B33","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41467-021-20935-9","article-title":"Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors","volume":"12","author":"Valero","year":"2021","journal-title":"Nat Commun"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0639-4","article-title":"Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy","volume":"25","author":"Chowell","year":"2019","journal-title":"Nat Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf8399","article-title":"Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy","volume":"355","author":"Davoli","year":"2017","journal-title":"Science"},{"key":"B38","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1126\/science.aau0447","article-title":"Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response","volume":"364","author":"Mandal","year":"2019","journal-title":"Science"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-020-00752-4","article-title":"The association between tumor mutational burden and prognosis is dependent on treatment context","volume":"53","author":"Valero","year":"2021","journal-title":"Nat Genet"},{"key":"B43","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s41598-018-19146-y","article-title":"Prognostic significance of HALP (hemoglobin, albumin, lymphocyte and platelet) in patients with bladder cancer after radical cystectomy","volume":"8","author":"Peng","year":"2018","journal-title":"Sci Rep"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S102909","article-title":"In vitro-activated tumor-specific T lymphocytes prolong the survival of patients with advanced gastric cancer: A retrospective cohort study","volume":"9","author":"Kuai","year":"2016","journal-title":"OncoTargets Ther"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30797-1","article-title":"Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study","volume":"21","author":"Sanchez","year":"2020","journal-title":"Lancet Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"MMT43","DOI":"10.2217\/mmt-2020-0002","article-title":"Disparity in outcomes of melanoma adjuvant immunotherapy by demographic profile","volume":"7","author":"Ikeguchi","year":"2020","journal-title":"Melanoma Manage"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The challenges of tumor mutational burden as an immunotherapy biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.2276","article-title":"T-Cell-Inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028","volume":"37","author":"Ott","year":"2018","journal-title":". J Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2870","article-title":"Modulation of lymphocyte regulation for cancer therapy: A phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma","volume":"16","author":"Ralph","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01796-6","article-title":"Durvalumab plus tremelimumab in solid tumors: A systematic review","volume":"38","author":"Arru","year":"2021","journal-title":"Adv Ther"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2020.05.002","article-title":"A novel etiology of hypophysitis: Immune checkpoint inhibitors","volume":"49","author":"Fernandes","year":"2020","journal-title":"Endocrinol Metab Clinics North Am"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"New Engl J Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.15190\/d.2019.6","article-title":"Immunotherapy for melanoma brain metastases","volume":"7","author":"Fernandes","year":"2019","journal-title":"Discoveries"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.15190\/d.2019.4","article-title":"Immunotherapy for breast cancer: First FDA approved regimen","volume":"7","author":"Soare","year":"2019","journal-title":"Discoveries"},{"key":"B57","unstructured":"FDA Approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer2019"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"New Engl J Med"},{"key":"B59","unstructured":"Nivolumab (Opdivo) for Hodgkin lymphoma2016"},{"key":"B60","unstructured":"Pembrolizumab (KEYTRUDA) for classical Hodgkin lymphoma2017"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"B63","unstructured":"FDA Approves pembrolizumab for advanced melanoma2014"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm9072033","article-title":"Endocrinopathies associated with immune checkpoint inhibitor cancer treatment: A review","volume":"9","author":"Okura","year":"2020","journal-title":"J Clin Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-00448","article-title":"Pembrolizumab-induced thyroiditis: Comprehensive clinical review and insights into underlying involved mechanisms","volume":"102","author":"Delivanis","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02802-6","article-title":"Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free survival and overall survival in non-small cell lung cancer: an original cohort study","volume":"70","author":"Thuillier","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0507","article-title":"FDA Approval summary: Nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy","volume":"21","author":"Kazandjian","year":"2016","journal-title":"Oncologist"},{"key":"B68","article-title":"Endocrine dysfunction induced by immune checkpoint inhibitors","volume":"81","author":"Deligiannis","year":"2021","journal-title":"Medicina"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"New Engl J Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0418","article-title":"Histology of nivolumab-induced thyroiditis","volume":"28","author":"Neppl","year":"2018","journal-title":"Thyroid"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003540","article-title":"Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: Ongoing and future perspectives in rare genital cancers treatment","volume":"10","author":"Gambale","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B73","unstructured":"FDA Approves cemiplimab-rwlc for metastatic or locally advanced cutaneous squamous cell carcinoma2018"},{"key":"B74","volume-title":"LiverTox: Clinical and research information on drug-induced liver injury","year":"2022"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"key":"B76","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2217\/imt-2019-0132","article-title":"Endocrine adverse events related with immune checkpoint inhibitors: An update for clinicians","volume":"12","author":"Deligiorgi","year":"2020","journal-title":"Immunother"},{"key":"B77","unstructured":"FDA Approves new, targeted treatment for bladder cancer2016"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"B80","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1001\/jamaoncol.2018.4224","article-title":"Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: A phase 1 study","volume":"5","author":"Emens","year":"2019","journal-title":"JAMA Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.14310\/horm.2002.1754","article-title":"Endocrine sequelae of immune checkpoint inhibitors","volume":"16","author":"Ntali","year":"2017","journal-title":"Hormones"},{"key":"B82","unstructured":"Durvalumab (Imfinzi)2017"},{"key":"B83","unstructured":"Avelumab (BAVENCIO)2017"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0509","article-title":"Immune checkpoint inhibitors: Review and management of endocrine adverse events","volume":"21","author":"Gonz\u00e1lez-Rodr\u00edguez","year":"2016","journal-title":"Oncologist"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.180870","article-title":"Adverse events associated with immune checkpoint inhibitor treatment for cancer","volume":"191","author":"Esfahani","year":"2019","journal-title":"Can Med Assoc J"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0032","article-title":"Thyroid toxicity following immune checkpoint inhibitor treatment in advanced cancer","volume":"30","author":"Muir","year":"2020","journal-title":"Thyroid"},{"key":"B87","unstructured":"Common terminology criteria for adverse events (CTCAE) v5.02017"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1530\/EC-19-0473","article-title":"Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction","volume":"9","author":"Olsson-Brown","year":"2020","journal-title":"Endocrine Connections"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"New Engl J Med"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.3390\/cancers13081944","article-title":"Graves\u2019 disease during immune checkpoint inhibitor therapy (A case series and literature review)","volume":"13","author":"Peiffert","year":"2021","journal-title":"Cancers"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32132","article-title":"A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors","volume":"145","author":"Arnaud-Coffin","year":"2019","journal-title":"Int J Cancer"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"New Engl J Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1055\/a-0843-3366","article-title":"A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","author":"De Filette","year":"2019","journal-title":"Hormone Metab Res"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1530\/EC-20-0342","article-title":"Management of endocrine immune-related adverse events of immune checkpoint inhibitors: An updated review","volume":"9","author":"Stelmachowska-Bana\u015b","year":"2020","journal-title":"Endoc Connect"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-2535","article-title":"Acquired generalized lipodystrophy: A new cause of anti-PD-1 immune-related diabetes","volume":"42","author":"Jehl","year":"2019","journal-title":"Diabetes Care"},{"key":"B99","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1634\/theoncologist.2018-0470","article-title":"Endocrine-related adverse events related to immune checkpoint inhibitors: Proposed algorithms for management","volume":"25","author":"Del Rivero","year":"2020","journal-title":"Oncologist"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: A comprehensive retrospective review from a single institution","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocrine-Related Cancer"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.3390\/cancers13061464","article-title":"Thyroid dysfunction in lung cancer patients treated with immune checkpoint inhibitors (ICIs): Outcomes in a multiethnic urban cohort","volume":"13","author":"D\u2019Aiello","year":"2021","journal-title":"Cancers"},{"key":"B102","doi-asserted-by":"publisher","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Trans Med"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.06.002","article-title":"Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management","volume":"58","author":"Sznol","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"B104","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.imlet.2020.02.008","article-title":"Immune-mediated adverse effects of immune-checkpoint inhibitors and their management in cancer","volume":"221","author":"Jin","year":"2020","journal-title":"Immunol Lett"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.2289","article-title":"Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: A pooled analysis of randomized phase II and III trials","volume":"35","author":"Schadendorf","year":"2017","journal-title":"J Clin Oncol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/clinem\/dgaa458","article-title":"Immune checkpoint inhibitor-induced thyroid dysfunction is associated with higher body mass index","volume":"105","author":"Pollack","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0221-5","article-title":"Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade","volume":"25","author":"Wang","year":"2019","journal-title":"Nat Med"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0169","article-title":"Management of endocrine disease immune check point inhibitors-induced hypophysitis","volume":"181","author":"Albarel","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"102134","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors \u2013 a systematic review and meta-analysis","volume":"92","author":"Hussaini","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-4075","article-title":"Endocrine side effects induced by immune checkpoint inhibitors","volume":"98","author":"Corsello","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: A detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis secondary to cytotoxic T-Lymphocyte\u2013associated protein 4 blockade: Insights into pathogenesis from an autopsy series","volume":"186","author":"Caturegli","year":"2016","journal-title":"Am J Pathol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy-immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000293","article-title":"Endocrinological side-effects of immune checkpoint inhibitors","volume":"28","author":"Torino","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-050219-034237","article-title":"Annual review of medicine autoimmune endocrinopathies: An emerging complication of immune checkpoint inhibitors","volume":"72","author":"Quandt","year":"2021","journal-title":"Annu Rev Med"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12531","article-title":"Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy","volume":"7","author":"Okamoto","year":"2016","journal-title":"J Diabetes Invest"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14050","article-title":"Immune checkpoint inhibitor-induced type 1 diabetes: a systematic review and meta-analysis","volume":"36","author":"Akturk","year":"2019","journal-title":"Diabetic Med"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0291","article-title":"Immune checkpoint inhibitors and type 1 diabetes mellitus: A case report and systematic review","volume":"181","author":"De Filette","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-018-1234-8","article-title":"Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype","volume":"56","author":"Marchand","year":"2019","journal-title":"Acta Diabetologica"},{"key":"B121","doi-asserted-by":"publisher","first-page":"bcr2016217454","DOI":"10.1136\/bcr-2016-217454","article-title":"Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma","volume":"2016","author":"Aleksova","year":"2016","journal-title":"BMJ Case Rep"},{"key":"B122","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1634\/theoncologist.2019-0555","article-title":"Immune checkpoint inhibitor-associated primary adrenal insufficiency: WHO VigiBase report analysis","volume":"25","author":"Grouthier","year":"2020","journal-title":"Oncologist"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01151","article-title":"Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies","volume":"104","author":"Piranavan","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000687","article-title":"Calcium-sensing receptor autoantibody-mediated hypoparathyroidism associated with immune checkpoint inhibitor therapy: diagnosis and long-term follow-up","volume":"8","author":"Dadu","year":"2020","journal-title":"J Immunotherapy Cancer"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02699-1","article-title":"Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: a systematic review","volume":"70","author":"Zhao","year":"2021","journal-title":"Cancer Immunology Immunotherapy"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra030158","article-title":"Autoimmune polyendocrine syndromes","volume":"552","author":"Eisenbarth","year":"2004","journal-title":"Adv Exp Med Biol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1210\/js.2018-00366","article-title":"Immune checkpoint blockade anti-PD-L1 as a trigger for autoimmune polyendocrine syndrome","volume":"3","author":"Lanzolla","year":"2019","journal-title":"J Endocrine Soc"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"New Engl J Med"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0116","article-title":"Immune-related thyroiditis with immune checkpoint inhibitors","volume":"28","author":"Iyer","year":"2018","journal-title":"Thyroid"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2018.10.019","article-title":"Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: Retrospective study of 105 patients","volume":"48","author":"Campredon","year":"2019","journal-title":"Presse Medicale"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ19-0234","article-title":"Comprehensive research on thyroid diseases associated with autoimmunity: autoimmune thyroid diseases, thyroid diseases during immune-checkpoint inhibitors therapy, and immunoglobulin-G4-associated thyroid diseases","volume":"66","author":"Inaba","year":"2019","journal-title":"Endocrine J"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.4158\/EP-2018-0472","article-title":"Baseline TSH level is associated with risk of anti\u2013PD-1\u2013induced thyroid dysfunction","volume":"25","author":"Pollack","year":"2019","journal-title":"Endocrine Pract"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2021.1958006","article-title":"Thyroid dysfunction and survival in cancer patients treated with immune checkpoint inhibitors: analyses from a large single tertiary cancer center database","volume":"60","author":"Percik","year":"2021","journal-title":"Acta Oncol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1186\/s40842-018-0073-4","article-title":"Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports","volume":"5","author":"Tan","year":"2019","journal-title":"Clin Diabetes Endocrinol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.critrevonc.2019.05.015","article-title":"Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders","volume":"141","author":"Jannin","year":"2019","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2300","article-title":"Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab","volume":"101","author":"De Filette","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B137","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.lungcan.2021.08.009","article-title":"Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC","volume":"161","author":"Zhou","year":"2021","journal-title":"Lung Cancer"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m736","article-title":"Autoimmune complications of immunotherapy: pathophysiology and management","volume":"369","author":"Chan","year":"2020","journal-title":"The BMJ"},{"key":"B139","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00262-020-02664-y","article-title":"Improved survival in patients with thyroid function test abnormalities secondary to immune-checkpoint inhibitors","volume":"70","author":"Lima Ferreira","year":"2021","journal-title":"Cancer Immunology Immunotherapy"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0075","article-title":"Immune checkpoint inhibitor-induced thyroiditis is associated with increased intrathyroidal T lymphocyte subpopulations","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"key":"B141","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1158\/2326-6066.CIR-18-0245","article-title":"Autoantibody development under treatment with immune-checkpoint inhibitors","volume":"7","author":"De Moel","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14363","article-title":"Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors","volume":"111","author":"Kurimoto","year":"2020","journal-title":"Cancer Sci"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.01.007","article-title":"Hashimoto thyroiditis: Clinical and diagnostic criteria","volume":"13","author":"Caturegli","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ20-0371","article-title":"Distinct clinical features and prognosis between persistent and temporary thyroid dysfunctions by immune-checkpoint inhibitors","volume":"68","author":"Inaba","year":"2021","journal-title":"Endocrine J"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0250","article-title":"PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.4103\/ijmr.IJMR_313_19","article-title":"The side effects of immune checkpoint inhibitor therapy on the endocrine system","volume":"154","author":"Goyal","year":"2021","journal-title":"Indian J Med Res"},{"key":"B147","doi-asserted-by":"publisher","first-page":"36","DOI":"10.4158\/EP-2019-0244","article-title":"Thyroid dysfunction, recovery, and prognosis in melanoma patients treated with immune checkpoint inhibitors: A retrospective review","volume":"26","author":"Al Mushref","year":"2020","journal-title":"Endocrine Pract"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.5012","article-title":"Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer","volume":"6","author":"Shankar","year":"2020","journal-title":"JAMA Oncol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00318","article-title":"Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody","volume":"37","author":"Maher","year":"2019","journal-title":"J Clin Oncol"},{"key":"B150","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12902-022-01004-8","article-title":"Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients","volume":"22","author":"Baek","year":"2022","journal-title":"BMC Endocrine Disord"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28973","article-title":"Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival","volume":"136","author":"De Remigis","year":"2015","journal-title":"Int J Cancer"},{"key":"B152","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/0284185120916197","article-title":"Morphological changes of the thyroid gland as a new radiographic marker for lung cancer treatment efficacy of immune checkpoint inhibitors","volume":"62","author":"Itonaga","year":"2021","journal-title":"Acta Radiologica"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2017.11.002","article-title":"Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma","volume":"5","author":"Angell","year":"2018","journal-title":"Genes Dis"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0208","article-title":"Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy","volume":"5","author":"Lee","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B156","doi-asserted-by":"publisher","first-page":"140092","DOI":"10.1530\/EDM-14-0092","article-title":"A novel melanoma therapy stirs up a storm: ipilimumab-induced thyrotoxicosis","volume":"2015","author":"Yu","year":"2015","journal-title":"Endocrinology Diabetes Metab Case Rep"},{"key":"B157","doi-asserted-by":"publisher","first-page":"2016:bcr2016214603","DOI":"10.1136\/bcr-2016-214603","article-title":"A rare case of thyroid storm","author":"McMillen","year":"2016","journal-title":"BMJ Case Rep"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann Oncol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1159\/000501824","article-title":"Graves\u2019 disease induced by immune checkpoint inhibitors: A case report and review of the literature","volume":"8","author":"Brancatella","year":"2019","journal-title":"Eur Thyroid J"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-10-0833","article-title":"Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy","volume":"164","author":"Min","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1159\/000485742","article-title":"Severe inflammatory ophthalmopathy in a euthyroid patient during nivolumab treatment","volume":"7","author":"Campredon","year":"2018","journal-title":"Eur Thyroid J"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000001161","article-title":"Extraocular muscle enlargement and thyroid eye disease-like orbital inflammation associated with immune checkpoint inhibitor therapy in cancer patients","volume":"35","author":"Sagiv","year":"2019","journal-title":"Ophthalmic Plast Reconstructive Surg"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.3109\/01676830.2014.949792","article-title":"Thyroid-like ophthalmopathy in a euthyroid patient receiving ipilimumab","volume":"33","author":"McElnea","year":"2014","journal-title":"Orbit"},{"key":"B164","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.3390\/jcm8111842","article-title":"Investigation of the correlation between graves\u2019 ophthalmopathy and CTLA4 gene polymorphism","volume":"8","author":"Chen","year":"2019","journal-title":"J Clin Med"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.3109\/02713683.2014.993767","article-title":"Meta-analysis of association between the +49A\/G polymorphism of cytotoxic T-lymphocyte antigen-4 and thyroid associated ophthalmopathy","volume":"40","author":"Wang","year":"2015","journal-title":"Curr Eye Res"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gene.6364018","article-title":"Analysis of the CTLA-4, CD28, and inducible costimulator (ICOS) genes in autoimmune thyroid disease","volume":"4","author":"Ban","year":"2003","journal-title":"Genes Immun"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1159\/000490384","article-title":"European Thyroid association guideline for the management of graves\u2019 hyperthyroidism","volume":"7","author":"Kahaly","year":"2018","journal-title":"Eur Thyroid J"},{"key":"B168","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3803\/EnM.2019.34.1.29","article-title":"Graves\u2019 disease: Can it be cured","volume":"34","author":"Wiersinga","year":"2019","journal-title":"Endocrinol Metab"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2020.100057","article-title":"Aspartic acid70 in the HLA-DRB1 chain and shared epitope alleles partially explain the high prevalence of autoimmunity in mexicans","volume":"3","author":"Vald\u00e9s-Corona","year":"2020","journal-title":"J Trans Autoimmun"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2017-0174","article-title":"Nivolumab-induced synchronous occurrence of myositis and hypothyroidism in a patient with squamous cell lung cancer","volume":"10","author":"Badovinac","year":"2018","journal-title":"Immunotherapy"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219835912","article-title":"Nivolumab-induced hypothyoidism with consequent hypothyroid related myopathy","volume":"26","author":"Johnson","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0213-x","article-title":"Nivolumab induced myxedema crisis","volume":"5","author":"Khan","year":"2017","journal-title":"J Immunotherapy Cancer"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2206","article-title":"Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy case report","volume":"29","author":"Chmiel","year":"2011","journal-title":"J Clin Oncol"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1145","article-title":"Endocrine toxicity of immune checkpoint inhibitors: Essential crosstalk between endocrinologists and oncologists","volume":"6","author":"Illouz","year":"2017","journal-title":"Cancer Med"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2020.906","article-title":"Characteristics of immune-related thyroid adverse events in patients treated with PD-1\/PD-L1 inhibitors","volume":"36","author":"Yoon","year":"2021","journal-title":"Endocrinol Metab"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0613","article-title":"The impact of high-dose glucocorticoids on the outcome of immune-checkpoint inhibitor\u2013related thyroid disorders","volume":"7","author":"Ma","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/2087525","article-title":"Treatment of ipilimumab induced graves\u2019 disease in a patient with metastatic melanoma","volume":"2016","author":"Azmat","year":"2016","journal-title":"Case Rep Endocrinol"},{"key":"B178","doi-asserted-by":"publisher","first-page":"988","DOI":"10.4158\/EP12280.GL","article-title":"Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American association of clinical endocrinologists and the American thyroid association","volume":"18","author":"Garber","year":"2012","journal-title":"Endocrine Pract"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1002\/cphy.c200003","article-title":"The role of thyroid hormone in the innate and adaptive immune response during infection","volume":"10","author":"Rubingh","year":"2020","journal-title":"Compr Physiol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1010279\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:37:00Z","timestamp":1663634220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1010279\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,20]]},"references-count":179,"alternative-id":["10.3389\/fendo.2022.1010279"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.1010279","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,20]]},"article-number":"1010279"}}